Breaking News
Get 55% Off 0
🎈 Up Big Today: Find today's biggest gainers with our free screener
Try Stock Screener
Close

Taisho Pharmaceutical Ind (SQBI_p)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
Taisho Pharma Ind historical data, for real-time data please try another search
440,000 0    0.00%
04/02 - Closed. Currency in IDR
Type:  Equity
Market:  Indonesia
ISIN:  ID2000069907 
  • Volume: 0
  • Bid/Ask: 420,000 / 460,000
  • Day's Range: 440,000 - 440,000
Taisho Pharma Ind 440,000 0 0.00%

JK:SQBI_p Financials

 
Explore the JK:SQBI_p financials. Find the Taisho Pharma Ind financial statements for a comprehensive overview of the company’s financial health. This summary highlights critical numbers from key financial reports, including the Taisho Pharma Ind annual report, the income statement, balance sheet, and cash flow statement. Gain deeper insights with financial ratios that assess the company's performance and stability. Users can customize their view by selecting data from four periods of either annual or quarterly information, making it easy to track the financial performance of Taisho Pharma Ind over time.

PT Taisho Pharmaceutical Indonesia Tbk reported earnings results for the full year ended December 31, 2023. For the full year, the company reported sales was IDR 550,973.01 million compared to IDR 790,151.29 million a year ago. Net income was IDR 80,685.55 million compared to IDR 250,318.45 million a year ago. Basic earnings per share from continuing operations was IDR 6,770 compared to IDR 25,070 a year ago.

AnnualQuarterly  
Advanced Financial Summary
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

SQBI_p Income Statement

Gross margin TTM -
Operating margin TTM -
Net Profit margin TTM -
Return on Investment TTM -
 Total Revenue  Net Income
Period Ending: Dec 31, 2017 Sep 30, 2017 Mar 31, 2017 Dec 31, 2016
Total Revenue 137341.49 440031.49 168224.71 143358.12
Gross Profit 86339.38 254023.63 99686.42 79898.87
Operating Income 54734.14 182666.05 73463.43 56070.78
Net Income 41262.9 137697.11 55300.81 42142.36

SQBI_p Balance Sheet

Quick Ratio MRQ -
Current Ratio MRQ -
LT Debt to Equity MRQ -
Total Debt to Equity MRQ -
 Total Assets  Total Liabilities
Period Ending: Dec 31, 2017 Sep 30, 2017 Mar 31, 2017 Dec 31, 2016
Total Assets 492349.22 437760.74 526170.18 479233.79
Total Liabilities 133919.13 119986.17 116263.75 124404.09
Total Equity 358430.1 317774.57 409906.42 354829.7

SQBI_p Cash Flow Statement

Cash Flow/Share TTM -
Revenue/Share TTM -
Operating Cash Flow  159.34%
 Cash  Net Change in Cash
Period Ending: Dec 31, 2017 Sep 30, 2017 Mar 31, 2017 Dec 31, 2016
Period Length: 12 Months 9 Months 3 Months 12 Months
Cash From Operating Activities 192234.29 131334.25 37989.84 179485.98
Cash From Investing Activities -8026.24 -5864.92 -1613.48 -8782.76
Cash From Financing Activities -173174 -173195.42 -163022.93
Net Change in Cash 11003.12 -48070.89 35257.86 6300.37
* In Millions of IDR (except for per share items)
InvestingPro
Go to Dashboard InvestingPro

Unlock access to over 1000 metrics with InvestingPro

View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.

 
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

SQBI_p Comments

Write your thoughts about Taisho Pharmaceutical Ind
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Apple
Continue with Google
or
Sign up with Email